The 11 references in paper D. Naskhletashvili R., A. Bekyashev Kh., V. Karakhan B., V. Aleshin A., R. Fu G., D. Belov M., E. Chmutin G., Д. Насхлеташвили Р., А. Бекяшев Х., В. Карахан Б., В. Алешин А., Р. Фу Г., Д. Белов М., Е. Чмутин Г. (2015) “КОМБИНИРОВАННАЯ ХИМИОТЕРАПИЯ С ВКЛЮЧЕНИЕМ ПРОКАРБАЗИНА (НАТУЛАН) В ЛЕЧЕНИИ АНАПЛАСТИЧЕСКИХ ОЛИГОДЕНДРОГЛИОМ // COMBINED CHEMOTHERAPY INCLUDING PROCARBAZINE (NATULAN) IN THE TREATMENT OF ANAPLASTIC OLIGODENDROGLIOMAS” / spz:neicon:ogsh:y:2012:i:1:p:14-16

1
Bauman G.S., Ino Y., Yeki K. et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys 2000;48:825–30.
(check this in PDF content)
2
Bello M.J., Leone P.E., Vaquero J., de Campos J.M., Kusac M.E., Sarasa J.I. et al. Allelic loss at 1p at 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207–10.
(check this in PDF content)
3
Caincross J.G., Macdonald D.R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360–4.
(check this in PDF content)
4
Ino Y., Betensky R.A., Ziatescu M.C., Sasaki H., Macdonald D.R. et al. Molekular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839.
(check this in PDF content)
5
Macdonald D.R., Gaspar L.E., Cairnocross J.G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990;27:573–4.
(check this in PDF content)
6
Pilo de la Fuente B., Dalmau J., Rosenfeld M. Actualization del tratamiento de los gliomas. Neurologia 2007; 22(3):159–69.
(check this in PDF content)
7
Reifenberger J., Reifenberger G., Liu L., James C.D., Wechsler W., Collins V.P. Molecular genetic analysis of oligodendroglioma tumors shows preferential allelic deletion 19q and 1p. Am J Pathol 1994;145:1175–90.
(check this in PDF content)
8
Smith J.S., Perry A., Borell T.J. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–45.
(check this in PDF content)
9
Soffietti R. Chemotherapy of anaplastic oligodendroglial tumors. Expert Opin Pharmacother 2004;5:295–306.
(check this in PDF content)
10
Bent M.J., Looijenga L.H., Langenberg K. et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276–84.
(check this in PDF content)
11
Vesper J., Graf E., Wille C., Tilgner J., Trippel M., Nikkhah G. and Ostertag C.B. Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. BMC Neurol 2009 Jul 16;9:33;
(check this in PDF content)